Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 921 GBX 0.71%
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Net Margin
Indivior PLC

-12.3%
Current
6%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.3%
=
Net Income
-141m
/
Revenue
1.1B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
UK
Indivior PLC
LSE:INDV
1.2B GBP
-12%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.9T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
17%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
19%
CH
Roche Holding AG
SIX:ROG
197B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP
13%
CH
Novartis AG
SIX:NOVN
169.8B CHF
35%
US
Pfizer Inc
NYSE:PFE
149.4B USD
7%
Country UK
Market Cap 1.2B GBP
Net Margin
-12%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 729.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.9T DKK
Net Margin
35%
Country US
Market Cap 347.8B USD
Net Margin
17%
Country US
Market Cap 248.3B USD
Net Margin
19%
Country CH
Market Cap 197B CHF
Net Margin
20%
Country UK
Market Cap 160.1B GBP
Net Margin
13%
Country CH
Market Cap 169.8B CHF
Net Margin
35%
Country US
Market Cap 149.4B USD
Net Margin
7%
No Stocks Found

Indivior PLC
Glance View

Market Cap
1.2B GBX
Industry
Pharmaceuticals

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
2 223 GBX
Undervaluation 59%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.3%
=
Net Income
-141m
/
Revenue
1.1B
What is the Net Margin of Indivior PLC?

Based on Indivior PLC's most recent financial statements, the company has Net Margin of -12.3%.